Norges Bank bought a new position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 115,000 shares of the biopharmaceutical company's stock, valued at approximately $551,000. Norges Bank owned 0.20% of Vanda Pharmaceuticals as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently bought and sold shares of the stock. SG Americas Securities LLC increased its position in Vanda Pharmaceuticals by 26.8% in the fourth quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company's stock worth $124,000 after buying an additional 5,459 shares in the last quarter. Verition Fund Management LLC grew its stake in shares of Vanda Pharmaceuticals by 7.8% during the 3rd quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company's stock valued at $189,000 after acquiring an additional 2,927 shares during the period. Franklin Resources Inc. increased its holdings in Vanda Pharmaceuticals by 8.8% in the 3rd quarter. Franklin Resources Inc. now owns 55,226 shares of the biopharmaceutical company's stock worth $266,000 after acquiring an additional 4,449 shares in the last quarter. BNP Paribas Financial Markets raised its stake in Vanda Pharmaceuticals by 1,184.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 62,238 shares of the biopharmaceutical company's stock worth $292,000 after acquiring an additional 57,393 shares during the period. Finally, KLP Kapitalforvaltning AS purchased a new position in Vanda Pharmaceuticals during the fourth quarter valued at approximately $649,000. 88.14% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on the stock. HC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of Vanda Pharmaceuticals in a research note on Tuesday, April 1st. StockNews.com started coverage on Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They issued a "hold" rating for the company.
View Our Latest Report on VNDA
Vanda Pharmaceuticals Stock Performance
Shares of Vanda Pharmaceuticals stock traded up $0.01 on Tuesday, hitting $4.37. 536,831 shares of the company traded hands, compared to its average volume of 903,855. The stock has a market capitalization of $254.84 million, a P/E ratio of -13.66 and a beta of 0.72. Vanda Pharmaceuticals Inc. has a 52 week low of $3.85 and a 52 week high of $6.75. The business has a 50-day simple moving average of $4.62 and a 200 day simple moving average of $4.69.
Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.06. The business had revenue of $53.19 million during the quarter, compared to analysts' expectations of $51.00 million. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. Research analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.
Insiders Place Their Bets
In other news, CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the stock in a transaction dated Friday, February 28th. The shares were purchased at an average cost of $4.76 per share, with a total value of $47,600.00. Following the completion of the purchase, the chief executive officer now directly owns 2,361,730 shares of the company's stock, valued at approximately $11,241,834.80. The trade was a 0.43 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. In the last three months, insiders have purchased 32,000 shares of company stock valued at $151,180. Company insiders own 8.90% of the company's stock.
About Vanda Pharmaceuticals
(
Free Report)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Featured Stories
Before you consider Vanda Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vanda Pharmaceuticals wasn't on the list.
While Vanda Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
